CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

51.59 +1.37 (+2.73%)

Delayed Quote Updated: 2:46 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

37 38 Next >

Where Will Vertex Pharmaceuticals Be in 10 Years? ↗

December 04, 2023

Vertex shares have soared 400% over the past decade.

Via The Motley Fool

If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today ↗

December 04, 2023

CRISPR Therapeutics' shares advanced in the double-digits this year.

Via The Motley Fool

Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now ↗

December 03, 2023

The one thing these two stocks have in common is tremendous growth prospects.

Via The Motley Fool

An Important History Lesson for Gene-Editing Investors ↗

December 02, 2023

Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.

Via The Motley Fool

5 Top Stocks to Buy Before 2024 ↗

December 02, 2023

These stocks have room to run -- next year and over the long term.

Via The Motley Fool

Five Best Performing Stocks Of The Top ETF Of November ↗

December 01, 2023

Most stocks in ARKK’s portfolio delivered strong returns in November. These five led the way.

Via Talk Markets

Topics ETFs

Is CRISPR Therapeutics the Best Gene-Editing Stock? ↗

November 22, 2023

The biotech's first-mover advantage bodes well for its long-term prospects.

Via The Motley Fool

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗

December 01, 2023

It's not as long a shot as some might think.

Via The Motley Fool

Looking for Growth? 2 Top Stocks to Buy Hand Over Fist ↗

December 01, 2023

These stocks offer enormous long-term growth potential.

Via The Motley Fool

3 Biotech Stocks That Could Be Multibaggers in the Making ↗

November 30, 2023

Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.

Via InvestorPlace

Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception ↗

November 29, 2023

The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014.

Via Benzinga

Topics ETFs

Jim Cramer: Buy Shares Of This Personal Computer Giant, Wait For 'A Little Bit Of Pullback' ↗

November 29, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here.

Via Benzinga

3 Top-Rated Biotech Stocks That Analysts Are Loving Now ↗

November 28, 2023

Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies.

Via InvestorPlace

2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market ↗

November 28, 2023

These stocks may take off in a market favoring growth.

Via The Motley Fool

Investing in These 3 Stocks Now Could Make You a Millionaire Retiree ↗

November 25, 2023

These innovators should have tremendous long-term growth prospects.

Via The Motley Fool

3 Biotech Stocks That Could Be Millionaire Makers ↗

November 22, 2023

Many biotech stocks offer exciting long-term growth prospects.

Via The Motley Fool

Are You A Trader Or Investor: Biotech Momentum Is Picking Up ↗

November 20, 2023

ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.

Via Talk Markets

Topics ETFs

What's Going On With Crispr Therapeutics Stock Monday? ↗

November 20, 2023

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday on what appears to be continued momentum from the recent regulatory authorization of the company's

Via Benzinga

Google’s Bard AI Says These 3 Stocks Will Rise 1,000% ↗

November 20, 2023

Google's Bard has been among the best stock pickers, and thinks these three stocks have quadruple-digit upside potential.

Via InvestorPlace

Topics Artificial Intelligence

2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street ↗

November 20, 2023

Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio?

Via The Motley Fool

Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire? ↗

November 19, 2023

The stock is trading below its peak, reached a couple of years ago.

Via The Motley Fool

3 Monster Stocks in the Making ↗

November 18, 2023

These stocks could grow much larger over the next few years.

Via The Motley Fool

Why CRISPR Therapeutics Stock Is Jumping Again Today ↗

November 17, 2023

The stock continues to enjoy momentum from a key regulatory approval.

Via The Motley Fool

Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday ↗

November 17, 2023

U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday.

Via Benzinga

Topics Stocks

CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News ↗

November 17, 2023

CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level.

Via Investor's Business Daily

3 Long-Term Growth Stocks Analysts Are Bullish On ↗

November 16, 2023

Here are three long-term growth stocks for your consideration if you’re looking to take a long position in a new name or two.

Via InvestorPlace

3 Cathie Wood You’ll Regret Not Buying Soon: November 2023 ↗

November 16, 2023

Cathie Wood thinks we're out of the woods economically, and these stock picks in her portfolio stand to gain the most in coming months.

Via InvestorPlace

Why Is NIO Stock Down 5% Today? ↗

November 16, 2023

Nio stock is falling on Thursday as investors react to negative news following the summit between Presidents Xi Jinping and Joe Biden.

Via InvestorPlace

Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug ↗

November 16, 2023

The drug will sell under the brand name Casgevy in the UK for two blood diseases.

Via Investor's Business Daily

What's Going On With Crispr Therapeutics Stock Thursday? ↗

November 16, 2023

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Thursday after the company announced regulatory authorization of the first CRISPR/Cas9 gene-

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.